medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2022-032medsovet-7529Research ArticleЭНДОКРИНОЛОГИЯENDOCRINOLOGYСовременный ингибитор натрий-глюкозного котранспортера 2-го типа – эртуглифлозинModern inhibitor of sodium-glucose cotransporter type 2 – ertugliflozinhttps://orcid.org/0000-0001-9390-1200ПетунинаН. А.PetuninaN. A.

Петунина Нина Александровна, чл.-корр. РАН, д.м.н., профессор, заведующая кафедрой эндокринологии 

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Nina A. Petunina, Corr. Member of RAS, Dr. Sci. (Med.), Professor, Head of the Department of Endocrinology 

8, Bldg. 2, Trubetskaya St., Moscow, 119991

napetunina@mail.ruhttps://orcid.org/0000-0001-7025-8427ГончароваЕ. В.GoncharovaE. V.

Гончарова Екатерина Валерьевна, к.м.н., доцент кафедры эндокринологии Института клинической медицины имени Н.В. Склифосовского 

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Ekaterina V. Goncharova, Cand. Sci. (Med.), Associate Professor of the Department of Endocrinology, Sklifosovsky Institute of Clinical Medicine 

8, Bldg. 2, Trubetskaya St., Moscow, 119991

goncharova_ev@list.ruhttps://orcid.org/0000-0001-8007-9721ТельноваМ. Э.ТеlnovaM. Е.

Тельнова Милена Эдуардовна, к.м.н., доцент, доцент кафедры эндокринологии Института клинической медицины имени Н.В. Склифосовского 

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Milena Е. Теlnova, Cand. Sci. (Med.), Associate Professor of the Department of Endocrinology, Sklifosovsky Institute of Clinical Medicine 

8, Bldg. 2, Trubetskaya St., Moscow, 119991

milena.telnova@mail.ruhttps://orcid.org/0000-0001-7923-4894КузинаИ. А.KuzinaI. A.

Кузина Ирина Александровна, ассистент кафедры эндокринологии Института клинической медицины имени Н.В. Склифосовского 

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Irina A. Kuzina, Teaching Assistant of the Department of Endocrinology, Sklifosovsky Institute of Clinical Medicine 

8, Bldg. 2, Trubetskaya St., Moscow, 119991

mia986@mail.ruhttps://orcid.org/0000-0002-0202-1257МартиросянН. С.MartirosyanN. S.

Мартиросян Нарине Степановна, к.м.н., доцент кафедры эндокринологии Института клинической медицины имени Н.В. Склифосовского 

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Narine S. Martirosyan, Cand. Sci. (Med.), Associate Professor of the Department of Endocrinology, Sklifosovsky Institute of Clinical Medicine 

8, Bldg. 2, Trubetskaya St., Moscow, 119991

narinarine@mail.ruhttps://orcid.org/0000-0002-1609-9645СочневаА. Ю.SochnevaA. Yu.

Сочнева Александра Юрьевна, ординатор кафедры эндокринологии Института клинической медицины имени Н.В. Склифосовского 

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Alexandra Yu. Sochneva, Resident of the Department of Endocrinology, Sklifosovsky Institute of Clinical Medicine 

8, Bldg. 2, Trubetskaya St., Moscow, 119991

alexandrasochneva@gmail.comПервый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation20231205202306234240Copyright © Петунина Н.А., Гончарова Е.В., Тельнова М.Э., Кузина И.А., Мартиросян Н.С., Сочнева А.Ю., 20232023Петунина Н.А., Гончарова Е.В., Тельнова М.Э., Кузина И.А., Мартиросян Н.С., Сочнева А.Ю.Petunina N.A., Goncharova E.V., Теlnova M.Е., Kuzina I.A., Martirosyan N.S., Sochneva A.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/7529

Сахарный диабет общепризнан одним из основных факторов риска сердечно-сосудистых заболеваний (ССЗ), а пациенты с  сахарным диабетом 2  типа  (CД2) имеют более высокую частоту сердечно-сосудистой заболеваемости и  смертности по сравнению с лицами, не имеющими нарушений углеводного обмена. Установлено, что гипергликемия является основным фактором риска развития ишемической болезни сердца и смертности. В реальной клинической практике врачи сталкиваются с  проблемой выбора при назначении новых сахароснижающих препаратов у  пациентов с  СД2  и  высоким сердечнососудистым риском. Современные возможности и подходы к терапии СД2 способствовали созданию перспективного класса сахароснижающих препаратов, блокирующих почечную реабсорбцию глюкозы, – ингибиторов натрий-глюкозного котранспортера 2-го типа (иНГЛТ-2). Уникальный механизм ингибирования НГЛТТ-2 способствует не только улучшению гликемического контроля, но и оказывает кардио- и нефропротективные эффекты у пациентов с СД2 и с высоким кардиоваскулярным риском. Согласно современным рекомендациям при выборе тактики лечения пациентов с СД2 и наличием факторов риска сердечно-сосудистых заболеваний или подтвержденных атеросклеротических сердечно-сосудистых заболеваний предпочтение отдается агонистам рецепторов ГПП-1  и/или иНГЛТ-2  в  сочетании с  препаратом первой линии  – метформином. В данной статье представлены основные результаты эффективности и безопасности применения эртуглифлозина в ряде клинических исследований и его благоприятного влияния не только на гликемический контроль, но и на кардио- и нефропротективные эффекты. В статье также отражены ключевые результаты обширной программы рандомизированных клинических исследований VERTIS (eValuation of ERTugliflozinefficacy and Safety; оценка эффективности и безопасности эртуглифлозина): с включением пациентов с СД2 и установленным атеросклеротическим сердечно-сосудистым заболеванием (VERTIS CV), с СД2 и хронической болезнью почек 3-й стадии (VERTIS RENAL), а также VERTIS MONO, VERTIS MET, VERTIS SITA, VERTIS SU и VERTIS FACTORIAL.

Diabetes mellitus, a well-known risk of cardiovascular disease (CVD), in patients with type 2 diabetes mellitus (DM2) Hyperglycemia has been found to be an increased risk of coronary heart disease and mortality. In real clinical practice, physicians are faced with the problem of choice when prescribing new hypoglycemic drugs in patients with type 2 diabetes and high cardiovascular risk. Modern possibilities and approaches to the treatment of DM2 have contributed to the creation of a promising class of hypoglycemic drugs that block renal glucose reabsorption - inhibitors of the sodium-glucose cotransporter type 2 (iSGLT-2). The unique mechanism of SGLT2 inhibition not only improves glycemic control, but also has cardio- and nephroprotective effects in patients with DM2 and at high cardiovascular risk. According to current recommendations, when choosing the tactics of treating patients with DM2 and the presence of risk factors for cardiovascular diseases or confirmed atherosclerotic cardiovascular diseases, preference is given to GLP-1 and/or iSGLT-2 receptor agonists in combination with the first-line drug, metformin. This article presents the main results of the efficacy and safety of ertugliflozin in a number of clinical studies and its beneficial effect not only on glycemic control, but also on cardio- and nephroprotective effects. The article also reflects the key results of an extensive program of randomized clinical trials VERTIS (acronym for eValuation of ERTugliflozinefficacy and Safety; evaluation of the efficacy and safety of ertugliflozin): including patients with type 2 diabetes and established atherosclerotic cardiovascular disease (VERTIS CV), with type 2 diabetes and CKD 3rd stage (VERTIS RENAL), as well as VERTIS MONO, VERTIS MET, VERTIS SITA, VERTIS SU and VERTIS FACTORIAL.

сахарный диабет 2-го типагипергликемиясахароснижающая терапиякардиопротективные и нефропротективные эффектыхроническая болезнь почекtype 2 diabeteshyperglycemiahypoglycemic therapycardioprotective and nephroprotective effectschronic kidney diseaseReferencesBommer C., Heesemann E., Sagalova V., Manne-Goehler J., Atun R., Bärnighausen T. et al. The Global Economic burden of Diabetes in Adults Aged 20–79 Years: a Cost-Of-Illness Study. Lancet Diabetes Endocrinol. 2017;5(6):423–430. https://doi.org/10.1016/s2213-8587(17)30097-9.Bommer C., Heesemann E., Sagalova V., Manne-Goehler J., Atun R., Bärnighausen T. et al. The Global Economic burden of Diabetes in Adults Aged 20–79 Years: a Cost-Of-Illness Study. Lancet Diabetes Endocrinol. 2017;5(6):423–430. https://doi.org/10.1016/s2213-8587(17)30097-9.Chatterjee S., Khunti K., Davies M. J. Type 2 Diabetes. Lancet. 2017;389(10085):2239–2251. https://doi.org/10.1016/S0140-6736(17)30058-2.Chatterjee S., Khunti K., Davies M. J. Type 2 Diabetes. Lancet. 2017;389(10085):2239–2251. https://doi.org/10.1016/S0140-6736(17)30058-2.Cosentino F., Grant P.J., Aboyans V., Bailey C. J., Ceriello A., Delgado V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486.Cosentino F., Grant P.J., Aboyans V., Bailey C. J., Ceriello A., Delgado V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486.Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N. et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;(157):107843. https://doi.org/10.1016/j.diabres.2019.107843.Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N. et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;(157):107843. https://doi.org/10.1016/j.diabres.2019.107843.Eknoyan G., Lameire N., Wheeler D.C., Jadoul M., Winkelmayer W.C., Arici M et al. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. https://doi.org/10.1016/j.kint.2020.06.019.Eknoyan G., Lameire N., Wheeler D.C., Jadoul M., Winkelmayer W.C., Arici M et al. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. https://doi.org/10.1016/j.kint.2020.06.019.Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381. https://doi.org/10.1093/eurheartj/ehw106.Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381. https://doi.org/10.1093/eurheartj/ehw106.Дедов И.И., Шестакова М.В., Майоров А.Ю., Мокрышева Н.Г., Викулова О.К., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2021;24(1S):1–148. https://doi.org/10.14341/DM12802.Dedov I.I., Shestakova M.V., Mayorov A.Yu., Mokrysheva N.G., Vikulova O.K., Galstyan G.R. et al. Diabetes Mellitus. 2021;24(1S):1–148. (In Russ.) https://doi.org/10.14341/DM12802.Markham A. Ertugliflozin: First Global Approval. Drugs. 2018;78(4):513–519. https://doi.org/10.1007/s40265-018-0878-6.Markham A. Ertugliflozin: First Global Approval. Drugs. 2018;78(4):513–519. https://doi.org/10.1007/s40265-018-0878-6.Liu L., Shi F.H., Xu H., Wu Y., Gu Z.C., Lin H.W. Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Front Pharmacol. 2022;(12):752440. https://doi.org/10.3389/fphar.2021.752440.Liu L., Shi F.H., Xu H., Wu Y., Gu Z.C., Lin H.W. Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Front Pharmacol. 2022;(12):752440. https://doi.org/10.3389/fphar.2021.752440.Gerich J. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–142. https://doi.org/10.1111/j.1464-5491.2009.02894.x.Gerich J. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–142. https://doi.org/10.1111/j.1464-5491.2009.02894.x.Buse J.B., Wexler D.J., Tsapas A., Rossing P., Mingrone G., Mathieu C. et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–493. https://doi.org/10.2337/dci19-0066.Buse J.B., Wexler D.J., Tsapas A., Rossing P., Mingrone G., Mathieu C. et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–493. https://doi.org/10.2337/dci19-0066.Dagogo-Jack S., Liu J., Eldor R., Amorin G., Johnson J., Hille D. et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530–540. https://doi.org/10.1111/dom.13116.Dagogo-Jack S., Liu J., Eldor R., Amorin G., Johnson J., Hille D. et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20(3):530–540. https://doi.org/10.1111/dom.13116.Terra S.G., Focht K., Davies M., Frias J., Derosa G., Darekar A. et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721–728. https://doi.org/10.1111/dom.12888.Terra S.G., Focht K., Davies M., Frias J., Derosa G., Darekar A. et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721–728. https://doi.org/10.1111/dom.12888.Aronson R., Frias J., Goldman A., Darekar A., Lauring B., Terra S.G. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab. 2018;20(6):1453–1460. https://doi.org/10.1111/dom.13251.Aronson R., Frias J., Goldman A., Darekar A., Lauring B., Terra S.G. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab. 2018;20(6):1453–1460. https://doi.org/10.1111/dom.13251.Kovacich N., Chavez B. Ertugliflozin (Steglatro): A New Option for SGLT2 Inhibition. P T. 2018;43(12):736–742. Available at: https://pubmed.ncbi.nlm.nih.gov/30559584/.Kovacich N., Chavez B. Ertugliflozin (Steglatro): A New Option for SGLT2 Inhibition. P T. 2018;43(12):736–742. Available at: https://pubmed.ncbi.nlm.nih.gov/30559584/.Rosenstock J., Frias J., Pall D., Charbonnel B., Pascu R., Saur D. et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20(3):520–529. https://doi.org/10.1111/dom.13103.Rosenstock J., Frias J., Pall D., Charbonnel B., Pascu R., Saur D. et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20(3):520–529. https://doi.org/10.1111/dom.13103.Miller S., Krumins T., Zhou H., Huyck S., Johnson J., Golm G. et al. Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. Diabetes Ther. 2018;9(1):253–268. https://doi.org/10.1007/s13300-017-0358-0.Miller S., Krumins T., Zhou H., Huyck S., Johnson J., Golm G. et al. Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. Diabetes Ther. 2018;9(1):253–268. https://doi.org/10.1007/s13300-017-0358-0.Hollander P., Liu J., Hill J., Johnson J., Jiang Z.W., Golm G. et al. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Diabetes Ther. 2018;9(1):193–207. https://doi.org/10.1007/s13300-017-0354-4.Hollander P., Liu J., Hill J., Johnson J., Jiang Z.W., Golm G. et al. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Diabetes Ther. 2018;9(1):193–207. https://doi.org/10.1007/s13300-017-0354-4.Hollander P., Hill J., Johnson J., Wei Jiang Z., Golm G., Huyck S. et al. Results of VERTIS SU extension study: Safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin. 2019;35(8):1335–1343. https://doi.org/10.1080/03007995.2019.1583450.Hollander P., Hill J., Johnson J., Wei Jiang Z., Golm G., Huyck S. et al. Results of VERTIS SU extension study: Safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin. 2019;35(8):1335–1343. https://doi.org/10.1080/03007995.2019.1583450.Pratley R.E., Eldor R., Raji A., Golm G., Huyck S.B., Oiu Y. et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111–1120. https://doi.org/10.1111/dom.13194.Pratley R.E., Eldor R., Raji A., Golm G., Huyck S.B., Oiu Y. et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111–1120. https://doi.org/10.1111/dom.13194.Салухов В.В., Ильинская Т.А. Новый ингибитор SGLT2 эртуглифлозин: безопасная эффективность в управлении сахарным диабетом 2-го типа. Медицинский cовет. 2020;(7):32–41. https://doi.org/10.21518/2079-701X-2020-7-32-41.Salukhov V.V., Ilyinskay T.A. New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes. Meditsinskiy Sovet. 2020;(7):32–41. (In Russ.) https://doi.org/10.21518/2079-701X-2020-7-32-41.Cannon C.P., Pratley R., Dagogo-Jack S., Mancuso J., Huyck S., Masiukiewicz U. et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425–1435. https://doi.org/10.1056/NEJMoa2004967.Cannon C.P., Pratley R., Dagogo-Jack S., Mancuso J., Huyck S., Masiukiewicz U. et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425–1435. https://doi.org/10.1056/NEJMoa2004967.Lingvay I., Greenberg M., Gallo S., Shi H., Liu J., Gantz I. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy. Diabetes Obes Metab. 2021;23(7):1640–1651. https://doi.org/10.1111/dom.14385.Lingvay I., Greenberg M., Gallo S., Shi H., Liu J., Gantz I. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy. Diabetes Obes Metab. 2021;23(7):1640–1651. https://doi.org/10.1111/dom.14385.Wanner C., Inzucchi S.E., Lachin J.M., Fitchett D., Von Eynatten M., Mattheus M. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. https://doi.org/10.1056/NEJMoa1515920.Wanner C., Inzucchi S.E., Lachin J.M., Fitchett D., Von Eynatten M., Mattheus M. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. https://doi.org/10.1056/NEJMoa1515920.Neal B., Perkovic V., Matthews D.R. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(21):2099. https://doi.org/10.1056/NEJMc1712572.Neal B., Perkovic V., Matthews D.R. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(21):2099. https://doi.org/10.1056/NEJMc1712572.The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” Diabetes Care. 2022;45(1):S1–S2. https://doi.org/10.2337/dc22-SINT.The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” Diabetes Care. 2022;45(1):S1–S2. https://doi.org/10.2337/dc22-SINT.Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. https://doi.org/10.1056/NEJMoa1812389.Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. https://doi.org/ 10.1056/NEJMoa1812389.Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H. J.L., Charytan D.M. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744.Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H. J.L., Charytan D.M. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744.Cherney D., Charbonnel B., Cosentino F., Dagogo-Jack S., McGuire D. K., Pratley R. et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021;64(6):1256–1267. https://doi.org/10.1007/s00125-021-05407-5.Cherney D., Charbonnel B., Cosentino F., Dagogo-Jack S., McGuire D. K., Pratley R. et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021;64(6):1256–1267. https://doi.org/10.1007/s00125-021-05407-5.Grunberger G., Camp S., Johnson J., Huyck S., Terra S.G., Mancuso J.P. et al. Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. Diabetes Ther. 2018;9(1):49–66. https://doi.org/10.1007/s13300-017-0337-5.Grunberger G., Camp S., Johnson J., Huyck S., Terra S.G., Mancuso J.P. et al. Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. Diabetes Ther. 2018;9(1):49–66. https://doi.org/10.1007/s13300-017-0337-5.Liu H., Sridhar V.S., Lovblom L.E., Lytvyn Y., Burger D., Burns K. et al. Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes. Kidney Int Rep. 2021;6(8):2095–2104. https://doi.org/10.1016/j.ekir.2021.05.022.Liu H., Sridhar V.S., Lovblom L.E., Lytvyn Y., Burger D., Burns K. et al. Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes. Kidney Int Rep. 2021;6(8):2095–2104. https://doi.org/10.1016/j.ekir.2021.05.022.

The authors declare that there are no conflicts of interest present.